ROTOP Pharmaka GmbH

Welcome to our website.

We are happy to present you our products and services.

The ROTOP trademark stands for quality and dependability. We place great emphasis on staying in close contact with our clients and on providing optimal service for the best possible individual solutions.

The following pages provide you with information about our company and our products. We are available to you at any time by phone or email for questions or if you wish to place an order. We are also happy to talk with you in person. Please inquire with our customer service department for the field manager responsible for your area.



>> General Terms and Conditions (GTC) 05/2018

>> Attachment 1 Data Protection (GDPR) 05/2018

>> GMP Certificate


Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404

ROTOP to Develop and Commercialize Progenics’ PSMA-Targeted SPECT/CT Imaging Agent in Europe

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404 

Leading Radiopharmaceutical Company ROTOP to Develop and Commercialize Progenics’ PSMA-Targeted SPECT/CT Imaging Agent in Europe

NEW YORK, NY & DRESDEN, GERMANY, MAY 14, 2019, – Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, and ROTOP Pharmaka GmbH, a leading radiopharmaceuticals company focused on diagnostics and therapeutics, today announced an exclusive agreement under which ROTOP agreed to develop and commercialize 1404 in Europe. 1404 is Progenics’ prostate specific membrane antigen (PSMA)-targeted small molecule SPECT/CT imaging agent labeled with technetium-99m that is designed to visualize prostate cancer.

“This European partnership with ROTOP further expands the global reach of our PSMA-targeted prostate cancer portfolio and establishes a development path forward for 1404 in this important market, where SPECT/CT is the standard nuclear imaging modality,” said Mark Baker, Chief Executive Officer of Progenics. “ROTOP has deep experience developing, producing and distributing radiopharmaceutical products, which makes them well suited to advance the development of 1404 in Europe, and ultimately improve physician treatment decisions of prostate cancer.”

Under the terms of the agreement, ROTOP will receive an exclusive license to and will be responsible for the development, regulatory approvals and commercialization of 1404 in the covered European territory. In exchange, Progenics is eligible for double-digit, tiered royalties based on future sales of 1404 in Europe. 

In the coming months, ROTOP will hold an expert panel meeting with KOLs in the PSMA imaging field as well as regulatory experts to review existing data on 1404 and obtain guidance on the clinical development. Upon agreement on a path forward, ROTOP will request a meeting with European regulators and start a clinical trial in early 2020.

With the number of installed PET cameras in Europe being less than a third of the installed SPECT cameras and prostate cancer being the most frequent cancer in men, a capacity shortage is already being seen for PSMA PET imaging in Europe and this is expected to worsen once PSMA PET tracers are approved in Europe. 1404 will address this problem as the first-in-class PSMA tracer using SPECT scanners. A 1404-SPECT scan could be the key to change the management of a large number of patients who have limited access to PET.

“1404 is a complimentary fit to ROTOP’s growing product line of radiopharmaceuticals, particularly technetium-99m based imaging agents, for the diagnosis of a range of diseases, including cancers,” said Jens Junker, Chief Executive Officer of ROTOP. “Our collaboration with Progenics underscores our commitment to developing new nuclear medicine and molecular imaging products in parallel to our commercial operations, which distributes radiopharmaceutical products to more than 30 countries.”

About 1404, an Imaging Agent Targeting Prostate Specific Membrane Antigen 

Progenics' molecular imaging radiopharmaceutical product candidate 1404 targets the extracellular domain of prostate specific membrane antigen (PSMA), a protein amplified on the surface of > 95% of prostate cancer cells and a validated target for the detection of primary and metastatic prostate cancer. 1404 is labeled with Technetium-99m, a gamma-emitting isotope that is widely available, is easy to prepare, and is attractive for nuclear medicine imaging applications. The image created provides the opportunity to visualize cancer, potentially allowing for improved detection and staging, more precise biopsies, and a targeted treatment plan including active surveillance as a disease management tool.


Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agent for prostate cancer (PyL™); and imaging analysis technology (aBSI and PSMA AI). Progenics has two commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies Inc.

About ROTOP Pharmaka GmbH 

ROTOP Pharmaka is a leading pharmaceutical company that develops, produces and distributes cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.


Here you can find the official press release of Progencis:


>> Information <<

ROTOP Pharmaka has taken appropriate measures in order to be able to guarantee production and delivery capability over a longer period of time. The situation is continuously monitored by our crisis management team. Further measures will be taken, if necessary.


Telefon Icon  +49 (0) 351 - 26 310 210

Fax Icon  +49 (0) 351 - 26 310 313

 e-mail customer service

Office hours:

Mo - Thu 07:00 am - 05:00 pm
Fr 07:00 am - 04:00 pm